
CLAIMS

1. Use of a compound of formula II, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of IPF,



II

wherein

X is selected from oxygen and sulphur;

Ar denotes an aryl group optionally containing one or more nitrogen, oxygen, or sulphur atoms, and optionally substituted in any one or more positions with one or more identical or different substituents selected from the group of nitro, trifluoromethyl, C_1-C_6 straight chain and branched alkoxy, C_1-C_6 straight chain and branched alkyl; and

R' is selected from the group of hydrogen, C_1-C_6 straight chain or branched alkyl;

R is selected from the group of hydrogen; C_1-C_6 straight chain and branched alkyl, alkenyl, and alkynyl; C_3-C_6 cycloalkyl; acyl groups COR^1 wherein R^1 is selected from the group comprising or consisting of C_1-C_6 straight chain and branched alkyl, alkenyl, and alkynyl, C_3-C_6 cycloalkyl and phenyl.

2. The use of the compound or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein X is oxygen.

3. The use of the compound or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein Ar is an unsubstituted or substituted phenyl or naphthyl group.

4. The use of the compound or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein Ar is a substituted phenyl, wherein the one or more substituents are selected from the group of nitro and C_1-C_6 straight chain and branched alkoxy.

5. The use of the compound or pharmaceutically acceptable salt or solvate thereof according to any of the preceding claims, wherein R' is H or methyl, and R is H or an acyl group COR^1 wherein R^1 is a C_1-C_6 straight chain or branched alkyl.

6. The use of the compound or pharmaceutically acceptable salt or solvate thereof according to any of the preceding claims, wherein R’ is methyl and R is acetyl.

7. Use of a composition comprising the compound or pharmaceutically acceptable salt or solvate thereof according to any of the preceding claims in the manufacture of a medicament for the treatment of IPF.

8. The use of the composition according to claim 7, wherein the composition is formulated for inhalation.

9. The use of the compound according to any of claims 1-6 or the use of the composition according to claim 7 or claim 8, wherein the compound or composition is being administered by pulmonal, oral, and/or intravenous administration.

10. The use of the compound according to any of claims 1-6 or the use of the composition according to claim 7, wherein the compound or composition is being administered by inhalation.

11. A kit comprising

i) the compound according to any of claims 1-6 or the composition according to claim 7 or claim 8; and

ii) an inhaler.